Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanate and sulbactam combined with extended-spectrum penicillins against ticarcillin-resistant Enterobacteriaceae and pseudomonads.

@article{Jacobs1986ComparativeAO,
  title={Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanate and sulbactam combined with extended-spectrum penicillins against ticarcillin-resistant Enterobacteriaceae and pseudomonads.},
  author={Michael R Jacobs and Stephen C. Aronoff and S Johenning and Shigeru Yamabe},
  journal={The Journal of antimicrobial chemotherapy},
  year={1986},
  volume={18 2},
  pages={
          177-84
        }
}
The in-vitro synergistic activity of YTR 830, a new beta-lactamase inhibitor, combined with four extended-spectrum penicillins (ticarcillin, piperacillin, mezlocillin and apalcillin) against ticarcillin-resistant clinical isolates of Gram-negative enteric bacilli was compared with that of clavulanate and sulbactam. Synergy testing was performed with fixed concentrations of beta-lactamase inhibitors (8 mg/l) combined with doubling dilutions of beta-lactams in microdilution trays. Synergy was… Expand
Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate
  • R. Fass, R. Prior
  • Medicine, Biology
  • Antimicrobial Agents and Chemotherapy
  • 1989
TLDR
For relatively susceptible strains of members of the family Enterobacteriaceae, neither combination was predictably more active than the other, but relatively resistant strains were generally more susceptible to piperacillin-tazobactam. Expand
Beta-lactamase production in members of the family Enterobacteriaceae and resistance to beta-lactam-enzyme inhibitor combinations
TLDR
The results indicate that the level and type of beta-lactamase produced by members of the family Enterobacteriaceae are important determinants of susceptibility to beta- lactam-inhibitor combinations, especially ticarcillin-clavulanate. Expand
Studies to optimize the in vitro testing of piperacillin combined with tazobactam (YTR 830).
  • R. Jones, A. Barry
  • Biology, Medicine
  • Diagnostic microbiology and infectious disease
  • 1989
TLDR
The combination of piperacillin and the beta-lactamase inhibitor tazobactam (formerly YTR 830) was studied to determine optimal disk concentrations and dilution testing conditions and appears to be worthy of further in vivo trials guided by these or similar tentative in vitro susceptibility testing parameters. Expand
Comparative in-vitro activity of piperacillin and piperacillin plus tazobactam towards beta-lactamase producing clinical isolates.
TLDR
Findings are interesting above all in regard to the synergistic effect demonstrated against MR beta-lactamase producing staphylococci and the Klebsiella-Enterobacter-Serratia (KES) group. Expand
Tazobactam-piperacillin compared with sulbactam-ampicillin, clavulanic acid-ticarcillin, sulbactam-cefoperazone, and piperacillin for activity against beta-lactamase-producing bacteria isolated from patients with complicated urinary tract infections.
TLDR
Tazobactam-piperacillin showed a broad antibacterial spectrum against gram-negative and gram-positive bacteria, and against all beta-lactamase-producing bacteria tested the antibacterial activity was at least 4- to 64-fold stronger than that of p Piperacillin. Expand
In vitro activity of YTR 830.
TLDR
Combined with ampicillin or amoxicillin, all three inhibitors were active against beta-lactamase producing strains of Staphylococcus aureus, Haemophilus influenzae, Klebsiella, Citrobacter diversus, and all anaerobes except for Bacteroides fragilis homology group II. Expand
Piperacillin/tazobactam (YTR 830) combination. Comparative antimicrobial activity against 5889 recent aerobic clinical isolates and 60 Bacteroides fragilis group strains.
TLDR
Piperacillin/tazobactam appears to be a promising parenteral antimicrobial combination, with a spectrum effective against a wide variety of clinical pathogens. Expand
In vitro activity of piperacillin/tazobactam versus other broad-spectrum antibiotics against nosocomial gram-negative pathogens isolated from burn patients.
TLDR
The emergence of Acinetobacter spp as a dominant gram-negative pathogen in burn patients and its high level of resistance against most of the antibiotics tested except piperacillin/tazobactam and imipenem were significant in light of the epidemiology of burn infections and treatment. Expand
Different ratios of the piperacillin-tazobactam combination for treatment of experimental meningitis due to Klebsiella pneumoniae producing the TEM-3 extended-spectrum beta-lactamase
TLDR
The study shows that tazobactam is able to provide effective protection against piperacillin hydrolysis by the TEM-3 enzyme within the CSF, and Appropriate dosage regimens of various beta-lactam-tazobactsam combinations may deserve comparative studies in experimental meningitis caused by organisms producing extended-spectrum beta- lactamases. Expand
Evaluation of piperacillin-tazobactam in experimental meningitis caused by a beta-lactamase-producing strain of K1-positive Escherichia coli
TLDR
Combination treatment of piperacillin combined with tazobactam in experimental meningitis resulted in significantly better bactericidal activity in the cerebrospinal fluid. Expand
...
1
2
3
4
...